Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency and Adverse Reactions to Antimalarial Drugs in Lagos State, Nigeria

Asian Journal of Pharmaceutical and Health Sciences,2013,3,1,615-619.
Published:February 2013
Type:Research Article
Author(s) affiliations:

Akwaowo orok1, Adetayo fagbenro-beyioku1, Godswill iboma1, Adedayo mayowa1, Hilary okoh2, Olusola ajibaye2, Bamidele iwalokun2, katherine egbuna2, Chimere agomo2, Yetunde olukosi2, Oluwagbemiga aina2, Samuel akindele2, Vera enya2, Jumoke akinyele2, Philip agomo2

1Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos.

2Department of Biochemistry and Nutrition, Nigerian Institute of Medical Research, Yaba, Lagos.


Individuals lacking in Glucose-6-phosphate dehydrogenase (G6PD) enzyme are selective to the use of drugs as deficiency can predispose to oxidation and subsequent hemolysis of their red blood cell. This study was undertaken to evaluate the effect of G6PD enzyme deficiency and correlation with adverse drug reaction to anti-malarial drugs. G6PD determination was done using Randox diagnostic kits while malaria diagnosis was done using standard microscopy technique. A total of 100 participants, comprising 44 males and 56 females (designated as group A & B) were recruited for the study. Of these numbers, 28 were G6PD deficient and 72 had normal G6PD activity. G6PD deficiency were similar in males 12 (27.3%) and in females 16(28.6%) (P=0.885). There was no statistical difference in G6PD activity with malaria parasite density (MPD) estimation (P=0.585) despite the fact that those with low G6PD activity also had low MPD than those with normal G6PD activity (415.57 ± 297.07 and 697.86 ± 1516.42 respectively). Also, among the 12 individuals who reported to having adverse drug reaction to some anti-malarials, the outcome was not statistically significant (P=0.659 and P=0.528). In conclusion, there was no relationship between G6PD activity and adverse drug reaction.

GThe relationship between G6PD activity and Adverse drug reaction (ADR) among G6PD deficient individuals; n=28